Condensed Interim Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Expenses:
Consulting (Note 11)	$ 45,000	$ 45,000	$ 135,000	$ 90,000
Research and development (Note 10)	4,624	283,269	93,561	912,892
Selling, general and administrative (Notes 9 and 11)	79,049	116,163	200,696	310,987
Stock-based compensation (Notes 7 and 11)	14,923	80,267	75,936	336,107
Loss from operations	(143,596)	(524,699)	(505,193)	(1,649,986)
Interest income	3,089	0	9,375	0
Net loss	(140,507)	(524,699)	(495,818)	(1,649,986)
Other comprehensive loss
Currency translation differences	(1,878)	(22,525)	(1,742)	(46,409)
Total comprehensive loss	$ (142,385)	$ (547,224)	$ (497,560)	$ (1,696,395)
Net loss per share - basic and diluted (in dollars per share)	$ (0)	$ (0.01)	$ (0.01)	$ (0.02)
Weighted average number of common shares outstanding – basic and diluted (in shares)	91,422,569	91,422,569	91,422,569	91,422,569